Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is 1 of the champion performing pharma stocks successful 2025. Truist lifted the terms people connected Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $36 from $32 connected January 7 and maintained a Buy standing connected the shares, telling investors that the affordable medicines taxable remains charismatic going into 2026.

In a abstracted development, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced connected December 24 that S&P Global Ratings upgraded the company’s semipermanent issuer recognition standing to ‘BB+’ from ‘BB’ with a unchangeable outlook. Moody’s Ratings Agency besides affirmed the company’s B1a rating, revising its outlook to affirmative from stable

Management stated that the upgrades people a notable milestone successful Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) advancement towards attaining investment-grade status. S&P noted that the company’s adjusted leverage declined to 4.4x arsenic of September 30, 2025, and is anticipated to driblet beneath 4.25x successful the coming quarters and conscionable the threshold for the higher rating.

The bureau besides cited Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) concern strength, liquidity profile, and fiscal discipline, with it bouncing backmost to gross maturation pursuing 5 years of declines, with enactment from coagulated show successful branded medicines and stabilization successful generics.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, produces, and sells medicines. Its operations are divided into the US, Europe, and International Markets geographical segments. Each concern conception covers the full merchandise portfolio successful that region, including specialty, generics, and over-the-counter (OTC) products.

While we admit the imaginable of TEVA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.